Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis

ABSTRACT Intravenous natalizumab is an effective treatment for relapsing–remitting multiple sclerosis. However, the standard treatment interval of 4 weeks may be excessive for many patients. Personalized interval extension using therapeutic drug monitoring (TDM) can result in adequate drug exposure...

Descripció completa

Dades bibliogràfiques

Autors principals:	Stefan P. H. van denBerg, Alyssa A. Toorop, Femke Hooijberg, Gertjan Wolbink, Nivea M. F. Voelkner, Liza M. Y. Gelissen, Joep Killestein, Zoé L. E. vanKempen, Thomas P. C. Dorlo, Theo Rispens
Format:	Artigo
Idioma:	Inglês
Publicat:	Wiley 2025-06-01
Col·lecció:	CPT: Pharmacometrics & Systems Pharmacology
Matèries:	biologics neurology personalized medicine population pharmacokinetics precision medicine targeted‐mediated disposition
Accés en línia:	https://doi.org/10.1002/psp4.70014
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!